2026-06-30 · 2026-06 / week-5
AeroVironment Prices the Drones, Not the Restatement
AeroVironment Prices the Drones, Not the Restatement
Summary: AeroVironment (AVAV) trades at $143.27, down 65.7% from its 52-week high of $417.86. On June 22, 2026, the company filed an 8-K (Item 4.02) disclosing that its Q3 FY2026 financial statements should no longer be relied upon. The restatement added $87.3M to the quarterly net loss, bringing the restated 9-month loss to $328.3M, which already exceeds the full-year FY2026 guidance of $(218)-$(201)M by 57%. The guidance has not been updated. The same week, Arlington Capital Partners, the company's largest shareholder at 24.1%, pulled both its board directors. The 10-K for fiscal year ended April 30, 2026, has not been filed. When it arrives, it will show the full restated annual loss and force a guidance revision that the market has not priced.
Opportunity Ranking
| Rank | Idea | Discovery Lane | Why It May Be Best Now | Evidence Freshness | Catalyst Window | Near-Term >5% Move Case | Asymmetry | Main Reason to Reject |
|---|---|---|---|---|---|---|---|---|
| 1 | AeroVironment (AVAV) short: restatement + broken guidance + shareholder exit | U.S. large-cap / restatement / governance | 9M restated loss exceeds FY guidance by 57%; Arlington Capital pulled board seats; 10-K filing imminent; $728M debt from BlueHalo; 0% convertible at $322.40 deeply underwater | 8-K Item 4.02 June 22, 2026; 13D/A June 24, 2026; 10-Q/A June 22, 2026; price June 29, 2026 | 10-K filing (FY ended April 30, 2026); guidance revision; Q1 FY2027 earnings | 10-K reveals full restated loss and forces guidance revision; any negative commentary on Space segment or BlueHalo integration; 15-25% dump on filing | 30-45% downside to $80-100 range; 15-20% upside risk on defense sector rally or contract win | Defense contractor with real revenue ($1.9B); non-GAAP EBITDA positive; drone demand narrative could sustain multiple |
| 2 | uniQure (QURE) short: $211.5M equity raise above market | U.S. biotech / follow-on offering | $211.5M offering at $42.77; revenue only $3.56M Q1; $53.5M Q1 net loss; stock near 52-week high | 424B5 June 24, 2026; 8-K June 24, 2026; price June 29, 2026 | Offering shares enter float; AMT-130 commercialization timeline | Offering shares create selling pressure; any clinical setback triggers dump; 10-15% downside | 15-25% downside to $35-40 range; 20-30% upside risk on positive clinical data | Gene therapy pipeline with real clinical promise; $351M post-raise cash; AMT-130 data could justify valuation |
| 3 | Allogene Therapeutics (ALLO) short: $135M ATM vs $541M market cap | U.S. biotech / ATM dilution | $135M ATM filed June 22; zero revenue; $50.9M Q1 net loss; $467M cash post-offering; ALPHA3 Phase 2 data | 424B5 June 22, 2026; 10-Q May 13, 2026; price June 29, 2026 | ATM deployment; ALPHA3 EFS data mid-2027 | ATM selling at $2.21 adds ~61M shares (25% dilution); any clinical setback amplifies; 10-15% downside | 20-30% downside if ATM deploys; 30-40% upside risk on positive CAR-T data | $467M cash extends runway to 2029; encouraging ALPHA3 interim data; real pipeline with partnership potential |
Selected opportunity: AeroVironment (AVAV) short Why this one now: The convergence of three events in a single week creates the tightest catalyst cluster in the current U.S. short screen. On June 16, two Arlington Capital board directors resigned. On June 22, the company filed an 8-K disclosing that its Q3 financials required restatement, adding $87.3M to the net loss. On June 24, Arlington Capital filed a 13D/A reporting the resignations and confirming it has not designated successor directors. The 10-K for fiscal year ended April 30, 2026, has not been filed. The restated 9-month loss of $328.3M already exceeds the full-year guidance of $(218)-$(201)M by 57%. The guidance is mathematically impossible to achieve and has not been updated. Why it can jump or dump >5% soon: The 10-K filing is the binary catalyst. AVAV's fiscal year ended April 30, 2026. The 10-K is expected by late July 2026 at the latest. When filed, it will show the full restated annual loss, which must incorporate the $87.3M understatement. The company will be forced to revise FY2026 guidance or report actual FY2026 results that are dramatically worse than the March 10 guidance. The restated 9M loss of $328.3M means FY2026 actual losses will be at least $328M plus Q4 results. Even if Q4 is breakeven (optimistic given the Q3 trend), FY2026 net loss will be at least $328M, 57% above the guidance midpoint of $209.5M. The stock has already shown >5% daily moves: June 22 saw a drop from $167.11 to $151.33 (-9.4%) on the restatement filing, and June 25 saw a further drop to $136.68 (-9.7%). What should surprise the reader: The company's own FY2026 guidance, issued on March 10 and never updated, is already mathematically broken. The 9-month restated net loss of $328.3M exceeds the full-year guidance of $(218)-$(201)M. To hit the guidance midpoint of $209.5M, Q4 would need to generate $118.8M of net income. Q3's restated net loss was $243.9M. The idea of a $119M swing to profit in one quarter is not plausible. The guidance is not stale. It is dead. The market has not yet seen the 10-K that will confirm this.
The Setup
AeroVironment acquired BlueHalo on May 1, 2025, for approximately $1.85B in cash and stock, funded by $968.5M in equity issuance and $726.9M in 0% Convertible Senior Notes due 2030 with a conversion price of $322.40 per share. The acquisition added $728M in long-term debt (up from $30M pre-acquisition) and $2.46B in goodwill to the balance sheet. [1][2]
In January 2026, the company received a stop-work order on its BADGER phased array antenna contract for the Space Force's SCAR program. This triggered a goodwill impairment analysis for the Space reporting unit, resulting in a $151.3M impairment charge in Q3 FY2026. [3]
On June 22, 2026, the company filed an 8-K (Item 4.02) disclosing that the Q3 financial statements required restatement. The Space reporting unit's carrying value had not included an allocation of goodwill from acquired deferred tax assets and liabilities. The restatement added $89.4M to the loss from operations and $87.3M to the net loss for both the quarter and nine months ended January 31, 2026. [4]
The same 8-K disclosed that two directors appointed by Arlington Capital Partners, the company's largest shareholder at 24.1%, had resigned effective June 17. Arlington filed a 13D/A on June 24 confirming it has not designated successor directors. [4][5]
The Mispricing
The market sees AVAV as a defense technology pure-play whose stock has corrected on a non-cash accounting issue. The narrative is that demand for military drones (Switchblades, Pumas) remains robust, the backlog is at a record $1.1B, and the restatement is a one-time goodwill adjustment that does not affect cash flow.
The filings describe a different picture. The restated 9-month net loss of $328.3M already exceeds the full-year FY2026 guidance of $(218)-$(201)M. The guidance, issued on March 10, 2026, has not been updated despite the $87.3M restatement. The 10-K, which will incorporate the restatement into full-year results, has not been filed. [3][4]
The BlueHalo acquisition that triggered this chain of events added $728M in debt and $2.46B in goodwill. The SCAR program termination eliminated a revenue stream from the acquired Space business. The 0% convertible notes due 2030 carry a $322.40 conversion price, 125% above the current $143.27 market price. The notes cannot be economically converted. They must be repaid at maturity in 2030, creating a refinancing wall for a company burning cash on GAAP losses. [2]
Arlington Capital, which owns 24.1% of the company and was the seller of BlueHalo to AVAV, has pulled its board representation. This is not a routine governance change. A 24.1% owner removing its board seats signals either preparation to sell, loss of confidence in financial reporting, or distancing from accounting liabilities. [4][5]
Price
| Metric | Value | Source |
|---|---|---|
| Current price | $143.27 | Yahoo Finance, June 29, 2026 close |
| 52-week high | $417.86 | Yahoo Finance |
| 52-week low | $135.20 | Yahoo Finance |
| Drawdown from high | -65.7% | Calculated |
| Above 52-week low | +6.0% | Calculated |
| RSI(14) | 25.5 | Calculated from Yahoo Finance 1-month data |
| Market cap | ~$7.15B | 49.9M shares x $143.27 |
| Long-term debt | $727.9M | 10-Q/A, January 31, 2026 |
| Cash and equivalents | $289.9M | 10-Q/A, January 31, 2026 |
| Short-term investments | $297.3M | 10-Q/A, January 31, 2026 |
| Net debt | ~$140.7M | $727.9M - $587.2M (cash + ST investments) |
| Goodwill on balance sheet | $2.46B | 10-Q/A, January 31, 2026 |
| Convertible notes | 0% due 2030, conversion $322.40 | 10-Q/A |
| FY2026 revenue guidance | $1.85-1.95B | Earnings release, March 10, 2026 |
| FY2026 net loss guidance | $(218)-$(201)M | Earnings release, March 10, 2026 |
| 9M restated net loss | $328.3M | Original $241.0M + $87.3M restatement |
| Q3 restated net loss | $243.9M | Original $156.6M + $87.3M restatement |
Positioning
Arlington Capital Partners: 24.1% ownership, board seats vacated. Arlington Capital Partners V and VI collectively own 12,035,890 shares (24.1% of outstanding). Their ownership percentage has declined from 26.3% at the time of the BlueHalo acquisition due to share dilution from the equity issuance. On June 17, 2026, both Arlington-designated directors (David Wodlinger and Henry Albers) resigned from the board. The 13D/A filed June 24 confirms no successor directors have been designated. This reduces Arlington's governance influence to zero while maintaining its economic exposure. [5]
Director resignations coinciding with restatement. The resignations occurred on June 16, one day before the restatement 8-K was filed. The 8-K states the resignations are "not the result of any disagreement with management." However, the timing creates an inference: either Arlington was informed of the restatement before it was public and chose to exit the board, or the resignations and restatement are coincidental. Neither interpretation is reassuring for shareholders. [4]
Insider trading under 10b5-1 plan. Director Stephen Page sold 250 shares at $174.41 on June 15, 2026, under a Rule 10b5-1 trading plan adopted September 30, 2025. The sale is small (250 shares out of 49,001 held) and was executed before the restatement was disclosed. This is not a strong insider selling signal, but it confirms that the 10b5-1 plan was active in the period leading up to the restatement. [6]
Short interest and borrow: Not available in this research session. AVAV is a NasdaqGS large-cap with likely available borrow, but short interest data could not be verified. This is a missing-data note, not an inference.
Options chain: Not verified in this session. AVAV likely has liquid options given its market cap and trading volume (737,968 shares on June 29).
CFO transition. On April 13, 2026, the company announced that Sean Woodward would replace Kevin McDonnell as CFO effective May 1, 2026. McDonnell was CFO during the period that required restatement. The transition was announced before the restatement was discovered, but the optics of a CFO change during an accounting restatement are negative. [7]
Catalyst
Primary catalyst: 10-K filing for FY2026 (fiscal year ended April 30, 2026). The 10-K has not been filed. AVAV's fiscal year ends April 30. The 10-K is typically filed within 60-75 days, implying a late June to late July 2026 filing. The 10-K will incorporate the restatement into full-year results. The restated 9-month loss of $328.3M means the full-year loss will be at least $328M (assuming Q4 is breakeven, which is unlikely given the Q3 trend). The March 10 guidance of $(218)-$(201)M is mathematically impossible to achieve. The 10-K will force either a guidance revision or disclosure of actual FY2026 results that are dramatically worse than guidance. [3][4]
Secondary catalyst: Q1 FY2027 earnings (expected September 2026). The first quarter under the new CFO will provide visibility into whether the restatement issues are isolated to the Space reporting unit or reflect broader integration failures from the BlueHalo acquisition.
Reflexive catalyst: Arlington Capital selling. If Arlington decides to sell its 24.1% stake (12M shares), the selling pressure on a stock already at its 52-week low would be significant. Average daily volume is approximately 1M shares. A 12M share block represents 12 days of average volume. There is no filing evidence of selling yet, but the board resignation is a prerequisite for a 144 filing or block trade.
Tertiary catalyst: Space segment revenue deterioration. The SCAR program termination was the trigger for the goodwill impairment. If other Space contracts are at risk, further impairments could follow. The 10-K may disclose additional information about the Space segment's revenue trajectory and contract backlog.
Payoff Map
The restated 9-month loss of $328.3M creates a quantifiable gap to the FY2026 guidance of $(218)-$(201)M. The guidance midpoint is $209.5M. The 9-month actual is $328.3M. The gap is $118.8M, which would need to be offset by Q4 net income of $118.8M to hit guidance. Q3's restated net loss was $243.9M. A $119M swing to profit in one quarter is not supported by any filing evidence.
Top case (bullish for the stock, adverse for the short): 10-K filed with clean restated numbers, strong Q4 revenue ($500M+), Space segment stabilizes, new contracts announced, defense sector rallies on geopolitical tensions. Stock recovers to $180-200. Probability: 20%.
Base case: 10-K filed showing FY2026 net loss of $350-400M (well above guidance), guidance for FY2027 is cautious, Arlington Capital remains passive. Stock drops to $100-120 on the filing, then stabilizes as the market digests the non-cash nature of the restatement. Probability: 45%.
Bottom case: 10-K reveals additional accounting issues beyond the Space reporting unit, BlueHalo integration failures, further goodwill impairments, Arlington Capital files Form 144 to sell shares, defense budget cuts pressure the drone narrative. Stock drops to $60-80. Probability: 35%.
Price Target and Probability Map
| Scenario | Price Target | Probability | Rationale |
|---|---|---|---|
| Top (bullish reversal) | $185 | 20% | 10-K clean, Q4 strong, defense rally, Arlington re-engages |
| Base (guidance break) | $105 | 45% | 10-K shows $350-400M FY loss, guidance revised, Space segment weak |
| Bottom (cascading issues) | $70 | 35% | Additional impairments, Arlington sells, integration failures |
Probability-weighted EV: (0.20 x $185) + (0.45 x $105) + (0.35 x $70) = $37 + $47.25 + $24.50 = $108.75. Current price $143.27. Expected downside: -24.1% to the probability-weighted target.
What Would Prove This Wrong
10-K filed with FY2026 net loss at or below $250M. This would require Q4 to generate at least $78M of net income. If the 10-K shows this, the guidance was achievable and the restatement impact was overstated.
Arlington Capital designates successor directors. This would signal continued engagement and confidence in the company's governance.
New Space segment contracts replacing SCAR revenue. If the company announces a replacement contract for the terminated BADGER/SCAR program, the Space segment impairment case weakens.
Non-GAAP adjusted EBITDA of $265-285M confirmed in the 10-K. If the non-GAAP profitability is maintained, the market may shrug off the GAAP restatement as non-cash.
AVAV announces a share buyback or debt repayment. This would signal cash flow confidence and reduce the refinancing risk on the $728M debt.
Risk Audit
Strongest counterargument: The restatement is non-cash. It does not affect revenue, current assets, current liabilities, or operating cash flow. The company's non-GAAP adjusted EBITDA guidance of $265-285M remains intact. The defense drone business (Switchblades, Pumas) is unrelated to the Space segment and continues to see robust demand, as evidenced by the $1.1B funded backlog and $2.1B in bookings. The market already pricing a 65.7% decline may have overcorrected. A sophisticated counterparty would argue: you are shorting a profitable defense contractor on an accounting technicality while geopolitical demand for its core products is accelerating.
Most fragile assumption: That the 10-K filing will trigger a >5% dump. The market may have already priced in the restatement impact. The stock dropped from $167 to $137 in the week after the restatement, then recovered to $143. If the 10-K merely confirms what the market already knows, the reaction could be muted. The base case assumes the market has not fully priced the gap between guidance and restated actuals, but this assumption is unverified.
What the market may already know: The restatement was filed June 22. The 9-month restated loss can be calculated from public filings. Analysts following AVAV may have already adjusted their models. The 65.7% drawdown from the 52-week high may partially reflect this.
What could make the trade lose money even if the thesis is directionally right: A defense sector rally driven by geopolitical escalation could lift AVAV regardless of its company-specific issues. The drone narrative is powerful: Switchblades are being used in Ukraine, and defense spending is rising globally. If the market values AVAV on revenue and backlog rather than GAAP earnings, the restatement matters less. A short position could be squeezed by positive sector news even if the fundamental thesis is correct.
Liquidity / execution risks: AVAV is a NasdaqGS stock with ~1M daily volume. Borrow is likely available but cost is unverified. The stock has shown 10%+ daily swings. Short entry should be staged over 2-3 sessions to avoid shorting at an intraday low. Put options are likely available but premium costs are unverified.
Leverage risks: The $728M debt load increases financial fragility. If the company's credit rating is downgraded or the revolver is tightened, the refinancing risk on the 0% convertible due 2030 becomes acute. However, the company has $587M in cash and short-term investments, providing near-term liquidity.
Information reliability risks: All financial data is from primary SEC sources (8-K, 10-Q/A, earnings release). The restatement amount ($87.3M) is directly from the 8-K. The 9-month original loss ($241.0M) is from the earnings release. The guidance ($218-201M) is from the earnings release. The Arlington Capital ownership (24.1%) is from the 13D/A. Live short interest, borrow cost, and options chain data are not available in this research session.
Invalidation trigger: If the 10-K is filed and shows FY2026 net loss below $250M, or if Arlington Capital designates successor directors within 30 days, or if the company announces a new Space contract replacing SCAR revenue, the thesis is broken. Close the short.
Publish / revise / reject recommendation: Publish. The convergence of restatement, broken guidance, shareholder exit, and imminent 10-K creates a time-bounded asymmetric setup. The quantifiable gap between guidance and restated actuals is the differentiating insight.
Bottom Line
AeroVironment's FY2026 guidance of $(218)-$(201)M net loss is dead. The 9-month restated loss is $328.3M. The 10-K will confirm this. Arlington Capital, the 24.1% owner who sold BlueHalo to AVAV, has walked away from the board. The $728M in acquisition debt and the $322.40 convertible are permanent overhangs. The market sees a defense drone company with a non-cash accounting issue. The filings describe a company whose largest acquisition is generating impairments, whose guidance is mathematically impossible, and whose biggest shareholder has lost confidence. The 10-K filing is the trigger.
Best Trade Strategy
Direction: Short Preferred instrument: Common stock short, staged entry over 2-3 sessions. Put options (3-6 month expiry, strike $120-130) as alternative if borrow is expensive or unavailable. Common-stock stance: Short AVAV on any rally above $150. Scale into position over 2-3 sessions: 40% on day 1, 30% on day 2, 30% on day 3. Do not short below $135 (52-week low) as the risk-reward deteriorates. Options stance: Buy puts with 3-6 month expiry at $120-130 strike if available. This caps downside risk to the premium paid and avoids borrow costs. Sell calls at $180-200 to finance the puts if a synthetic short is preferred. TP: $105 (base case, 27% downside from $143) SL / invalidation: $180 (26% upside from $143). Close if 10-K shows FY2026 net loss below $250M, or if Arlington designates successor directors, or if new Space contract replaces SCAR revenue. Timeline: 4-8 weeks (10-K filing expected by late July 2026) Execution risks: 10%+ daily volatility; defense sector news can trigger squeezes; borrow cost unverified; options liquidity unverified. Do-not-trade conditions: Do not short if AVAV has rallied >10% in the prior 24 hours on positive news. Do not short if a major defense spending bill is being announced. Do not short below $135 (52-week low). Monitoring checklist: (1) EDGAR for 10-K filing; (2) EDGAR for 8-K with guidance revision; (3) EDGAR for Form 144 filings from Arlington Capital; (4) EDGAR for new 13D/A from Arlington; (5) Yahoo Finance for price and volume; (6) Any Space Force contract announcements.
Research Quality Scorecard
| Criterion | Score | Rationale |
|---|---|---|
| Market disagreement | 5 | Clear price-positioning-catalyst tension: stock prices drone narrative, filings show broken guidance and shareholder exit |
| Evidence base | 5 | All financial data from primary SEC sources (8-K Item 4.02, 10-Q/A, earnings release, 13D/A) with timestamps within 8 days |
| Positioning and flows | 3 | Arlington Capital 24.1% ownership and board exit well-evidenced from 13D/A; missing live short interest, borrow cost, and options chain data |
| Catalyst path | 5 | 10-K filing is an observable, dated catalyst expected within 4-8 weeks; guidance revision is mechanical |
| Payoff architecture | 4 | Asymmetric with defined downside ($105 base, $70 bottom) and defined invalidation ($180); probability-weighted EV is -24% |
| Invalidation discipline | 5 | Explicit, monitorable triggers: 10-K loss below $250M, Arlington re-engagement, new Space contract |
| Differentiated insight | 5 | Non-obvious: 9M restated loss exceeds FY guidance by 57%; guidance is mathematically impossible and unupdated |
| Client value | 4 | Useful even without a trade: understanding that a $7B defense contractor's guidance is broken and its largest shareholder has exited governance |
| Total | 36/40 | Publish-ready Deep Dive |
Sources
| # | Source | Date | Key Data |
|---|---|---|---|
| 1 | 8-K Item 4.02 (Accession 0001104659-26-076140) | June 22, 2026 | Restatement disclosure, $87.3M net loss understatement, director resignations |
| 2 | 10-Q/A (Accession 0001104659-26-076141) | June 22, 2026 | Restated financials, convertible notes at $322.40, $727.9M long-term debt, $2.46B goodwill |
| 3 | Earnings Release Ex 99.1 (Accession 0001104659-26-025841) | March 10, 2026 | Q3 FY2026 results, FY2026 guidance, SCAR program termination, $151.3M goodwill impairment |
| 4 | 8-K Item 5.02 (Accession 0001104659-26-076140) | June 22, 2026 | Director resignations, Arlington Capital designees |
| 5 | Schedule 13D/A (Accession 0001104659-26-077403) | June 24, 2026 | Arlington Capital 24.1% ownership, no successor directors designated |
| 6 | Form 4 (Accession 0001184178-26-000016) | June 16, 2026 | Stephen Page 10b5-1 sale of 250 shares at $174.41 |
| 7 | 8-K Ex 99.1 (Accession 0001104659-26-042388) | April 13, 2026 | CFO transition announcement |
| 8 | Yahoo Finance | June 29, 2026 | Price $143.27, 52-week range, volume data |
Illustration Prompt
A high-value, editorial illustration for a financial research publication. The scene depicts a sleek military surveillance drone silhouetted against a dark sky, its rotors frozen mid-spin, casting a shadow over a crumbling balance sheet made of stone. Cracks run through the stone where the numbers $328M and $218M are carved, with the larger number breaking through the smaller one. In the background, a corporate boardroom with two empty chairs, leather seats untouched, suggesting recent departure. The color palette is deep navy, slate gray, and amber warning light. Style: realistic, high-end, elite, like a cover for The Economist or Bloomberg Markets feature. The image must include a subtle but clear watermark reading "The Mispricing Desk" in the lower right corner. No generic stock-photo language. The composition should convey the tension between a powerful defense technology and the financial cracks beneath it.